Home › Non-Small Cell Lung Cancer › Washington
Non-Small Cell Lung Cancer clinical trials in Washington
85 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Washington.
Cities in Washington
- Seattle55 studies
- Tacoma18 studies
- Spokane Valley15 studies
- Kirkland13 studies
- Spokane10 studies
- Vancouver9 studies
- Renton9 studies
- Kennewick3 studies
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Vista Oncology Inc PS, Olympia
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Nov 13, 2026 · NCT05920356A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Virginia Mason Medical Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07488676This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- American Oncology Network Vista Oncology Division-West office, Olympia
- American Oncology Network Vista Oncology Division-East office, Olympia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06758401Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06498635BostonGene and Exigent Genomic INsight Study
- Northwest Medical Specialities, Puyallup
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06272864Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Kadlec Clinic Hematology and Oncology, Kennewick
- Valley Medical Center, Renton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04267848A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Swedish Cancer Institute Medical Oncology, Edmonds
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06270706Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Northwest Medical Specialties - Gig Harbor, Gig Harbor
- Northwest Medical Specialties - Puyallup Medical Oncology, Puyallup
- Northwest Medical Specialties - Tacoma, Tacoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06472245Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04886804A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Virginia Mason Medical Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Medical Oncology Associates, Spokane
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07503808Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Local Institution - 0283, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07680790Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Tacoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07291037LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- MultiCare Regional Cancer Center, Auburn
- MultiCare Regional Cancer Center, Gig Harbor
- MultiCare Regional Cancer Center, Puyallup
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06216301A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Swedish Cancer Institute ( Site 0143), Seattle
- St. Joseph Medical Center Hematology and Oncology - Silverdale ( Site 0192), Silverdale
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06623422A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Fred Hutchinson Cancer Center ( Site 3202), Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07513376A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Local Institution - 0515, Edmonds
- Local Institution - 0499, Lacey
- Local Institution - 0508, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06561386A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- American Oncology Network Vista Oncology Division-West office, Olympia
- American Oncology Network Vista Oncology Division-East office, Olympia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07144280Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07388524Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Swedish Cancer Institute - Edmonds, Edmonds
- Swedish Medical Center, Seattle
- Cancer Care Northwest - Vercler, Spokane Valley
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06890598A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Summit Cancer Center, Spokane
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06150664A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06706076Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Swedish Cancer Institute, Everett
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Kaiser Permanente Bellevue Medical Center, Bellevue
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Swedish Cancer Institute-Edmonds, Edmonds
- and 8 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06418204A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Swedish Cancer Institute - Edmonds, Edmonds
- Kadlec Clinic Hematology and Oncology, Kennewick
- Swedish Medical Center, Seattle
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06119581Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center - Montlake, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT03191149A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Swedish Cancer Institute, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05498428Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Medical Oncology Associates - Summit Cancer Centers, Spokane
RecruitingPhase 3
Ages 18 to 90 · All sexes · Updated Nov 2, 2026 · NCT06745908Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Swedish Cancer Institute, Edmonds
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07185997Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center, Vancouver
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT04613596DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA09-0, Puyallup
- USA07-0, Spokane
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06953089A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Olympia
- Research Site, Seattle
- Research Site, Spokane
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06692738A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Valley Medical Center /ID# 253950, Renton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT04928846Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Tacoma
- Research Site, Vancouver
- Research Site, Wenatchee
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06357533Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Vista Oncology - East Olympia /ID# 275438, Olympia
- Northwest Medical Specialties Tacoma /ID# 270469, Tacoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06772623Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Fred Hutchinson Cancer Center, Seattle
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04981119Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Summit Cancer Treatment Center, Spokane
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT06899126A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Local Institution - 0384, Spokane
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07361510A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Medical Oncology Associates - Spokane /ID# 277172, Spokane
- Northwest Medical Specialties Tacoma /ID# 270534, Tacoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06568939Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Edmonds
- Research Site, Seattle
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Oct 21, 2026 · NCT05061550From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.